Skip to content
Markets News
Earnings1 min read

Pfizer Raises 2026 Forecast After Third-Quarter Results Beat Estimates

Makkler Newsroom
November 3, 2026 · Based on reporting by CNBC

Pfizer lifted its revenue and adjusted-profit outlook after quarterly sales and adjusted earnings exceeded analyst expectations.

Key takeaways

  • Pfizer raised its 2026 revenue outlook to $62 billion to $64 billion.
  • Adjusted third-quarter earnings were 87 cents per share, above the 73-cent estimate.
  • Cecile Guegan became Pfizer’s CFO this month after serving as interim CFO since August.

Pfizer raised its full-year revenue and adjusted-profit forecasts after third-quarter results beat analyst estimates. The company cited strong year-to-date performance and ongoing cost cuts.

The drugmaker now expects revenue of $62 billion to $64 billion, up from its prior range of $60.5 billion to $62.5 billion. Its adjusted profit forecast is $2.95 to $3.05 per share, compared with $2.80 to $3 previously.

Third-quarter adjusted earnings came in at 87 cents per share, above the 73 cents analysts expected, based on an LSEG survey. Revenue was $16.58 billion, topping the $15.87 billion estimate and roughly flat from a year earlier.

Sales of Eliquis rose 25% to $2.52 billion. Pfizer’s COVID-19 vaccine brought in $808 million, while Paxlovid sales were $449 million; both products beat analyst expectations.

Net income fell to $3.24 billion, or 56 cents per share, from $3.54 billion, or 62 cents per share, in the same quarter of 2025. Pfizer also named Cecile Guegan chief financial officer this month. She had served as interim CFO since August.

Pfizer is targeting about $9.7 billion in net savings through 2029 under its expanded cost-cutting plan.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.